Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 328

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 328
---
 transaction candidates through outreach to a variety of life sciences companies and prospective strategic partners. The Kineta management team conducted its discussions and negotiations with TuHURA principally through Kineta’s President, Mr. Philips. The TuHURA management team conducted its discussions and negotiations with Kineta through TuHURA’s CEO, Dr. Bianco. Following is a summary of the events leading up to the decision by Kineta to explore strategic alternatives, the process undertaken by Kineta to identify and evaluate prospective counterparties, and the negotiation of the Merger Agreement with TuHURA. The following chronology summarizes the key meetings and events that led to the signing of the agreements. The following chronology does not catalogue every conversation among the respective parties, their boards of directors and management, their respective representatives, or other parties. Kineta has regularly evaluated its long-term strategic goals and plans, its operations and financial performance, and overall industry conditions. As part of these evaluations, Kineta has considered, among other things, potential opportunities for strategic partnerships and collaborations, business combinations, acquisitions and other financial and strategic alternatives, including a sale of the Company. 206

On February 25, 2024, a meeting of the Kineta Board of Directors was held via
videoconference, which representatives of Kineta management and Orrick, Herrington & Sutcliffe LLP, the Company’s legal counsel (“Orrick”), attended. At the meeting, Kineta management detailed for the Kineta Board of
Directors that certain investors in the second tranche of the Company’s previously disclosed contemplated private placement, which was scheduled to occur on April 15, 2024, had notified the Company that they would not fulfill their funding
obligations under the securities purchase agreement dated June 15, 2022, as amended. As a result, the Company determined that it would have insufficient cash to continue to finance its operations. Also at this meeting, Kineta management
provided the Kineta Board of Directors with an overview of Kineta’s efforts to pursue alternative funding and income options for monetizing the VISTA asset and other Company assets included those previously licensed to third parties, including
discussions with venture capital firms, pharmaceutical companies and biotech royalty aggregator companies. Kineta management also provided an update on Kineta’s liquidity position and cash flow projections, including employee payment
obligations.

On February 29, 2024, the Kineta Board of Directors met informally via videoconference to discuss the launch of the
strategic alternatives outreach